The use of a GnRH antagonist (Cetrorelix®) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg

Human Reproduction

Volumn 13, Issue 9, 1998, Pages 2411-2414

  Olivennes, F ^a   Alvarez, S ^b   Bouchard, P ^c   Fanchin, R ^a   Salat Baroux, J ^b   Frydman, R ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b HÔPITAL TENON   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cetrorelix ; Dose finding; GnRH antagonist; IVF embryo transfer

Indexed keywords

CETRORELIX; ESTRADIOL; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; OVARY FOLLICLE DEVELOPMENT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031661436     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/13.9.2411     Document Type: Article

References (10)

1. Albano, C., Smitz, J., Camus, M. et al. (1997) Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix® during ovarian stimulation. Fertil. Steril., 67, 917-922.
2. Diedrich, K., Diedrich, C., Santos, E. et al. (1994) Suppression of the endogenous LH-surge by the GnRH antagonist Cetrorelix® during ovarian stimulation Hum. Reprod., 9, 788-791.
3. Eibschitz, I., Belaish-Allart, J. and Frydman, R. (1986) In vitro fertilization management and results in stimulated cycles with spontaneous luteinizing hormone discharge. Fertil. Steril., 45, 231-234.
4. Frydman, R., Cornel, C., De Ziegler, D. et al. (1991) Prevention of premature luteinizing hormone and progesterone rise with a GnRH antagonist Nal-Glu in ovarian stimulation. Fertil. Steril., 56, 923-927.
5. Frydman, R., Cornel, C., De Ziegler, D. et al. (1992) Spontaneous LH surge can be reliably prevented by the timely administration of a GnRH antagonist (Nal-Glu) during the late follicular phase. Hum. Reprod., 7, 930-933.
6. Karten, M.J., Hoeger, C.A., Hooh, W.A. et al. (1990) The development of safer antagonists: strategy and status. In Bouchard, P., Haour, F., Franchimont, P. and Schatz, B. (eds), Recent Progress on GnRH and Gonadal Peptides. Elsevier, Paris, pp. 147-158.
7. Leroy, I., d'Acremont, M.F., Brailly-Tabard, S. et al. (1994) A single injection of a GnRH-a (Cetrorelix®) postpones the LH surge: further evidence for the role of GnRH during the LH surge. Fertil. Steril., 62, 461-467.
8. Olivennes, F., Fanchin, R., Bouchard, P. et al. (1994) The single or dual administration of the GnRH antagonist Cetrorelix® prevents premature LH surges in an IVF-embryo transfer program. Fertil. Steril., 62, 468-476.
9. Olivennes, F., Fanchin, R., Bouchard, P. et al (1995) Scheduled administration of GnRH antagonist (Cetrorelix®) on day 8 of in-vitro fertilization cycles: a pilot study. Hum. Reprod., 10, 1382-1386.
10. Ubaldi, F., Albano, C., Peukert, M. et al. (1996) A subtle progesterone rise after the administration of the GnRH antagonist Cetrorelix® in ICSI cycles. Hum. Reprod., 11, 1405-1407.